Here are 1-3 brief analogies for Jasper Therapeutics (JSPR):

• Jasper Therapeutics is like Illumina for preparing the body for advanced cell and gene therapies; while Illumina provides tools to read genetic information, Jasper provides agents to clear space for new cells.
• If companies like CRISPR Therapeutics are developing the specialized 'software' for gene editing, Jasper Therapeutics is developing the crucial 'hardware prep' – the conditioning agents that create a clean environment in the bone marrow for those new genetic instructions.
• Jasper Therapeutics aims to make complex stem cell transplants and gene therapies safer and more widely available, much like how Intuitive Surgical (maker of Da Vinci robots) has revolutionized and expanded the use of minimally invasive surgery.

Major Products of Jasper Therapeutics (JSPR)

• JSP191: A conditioning antibody in clinical development that clears hematopoietic stem cells from bone marrow prior to stem cell therapy or gene therapy.
• Engineered Hematopoietic Stem Cells Product Candidates: Products under development aimed at overcoming limitations of allogeneic and autologous gene-edited stem cell grafts.

As a clinical-stage biotechnology company, Jasper Therapeutics (JSPR) is primarily focused on the research and development of therapeutic agents, including its lead product candidate, JSP191. These products are currently in clinical development and have not yet received regulatory approval for commercial sale.

Therefore, Jasper Therapeutics does not currently have major commercial customers in the traditional sense, whether other companies or individual patients. Its "products" are being evaluated in clinical trials, and its current activities are centered on advancing these candidates through the development pipeline.

Upon potential future regulatory approval, the company's customer base would likely consist of hospitals, specialized medical centers, and healthcare systems that administer complex therapies like stem cell transplantation and gene therapies to patients.

Jeet Mahal, Chief Executive Officer

Mr. Mahal was appointed Chief Executive Officer of Jasper Therapeutics effective January 5, 2026, after serving as Chief Business and Financial Officer, and most recently Chief Operating Officer. He joined Jasper Therapeutics from Portola Pharmaceuticals, where he spent 11 years in leadership roles, including Vice President, Business Development and Vice President, Strategic Marketing. At Portola, he successfully executed multiple business development partnerships for Andexxa®, Bevyxxa®, and cerdulatinib and played a key role in the company's equity financings, including its initial public offering. Earlier in his career, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development and strategic marketing team, and began his career in the drug development laboratories at COR Therapeutics.

Herb Cross, Chief Financial Officer

Mr. Cross joined Jasper Therapeutics as Chief Financial Officer in September 2023, bringing over two decades of financial leadership experience in public and private biotechnology companies. Prior to Jasper, he served as CFO at Atreca, where he led its initial public offering. Before Atreca, he was CFO at ARMO BioSciences, where he led its initial public offering and oversaw the company through its sale to Eli Lilly in 2018. Mr. Cross has also held CFO and interim CEO roles at KaloBios Pharmaceuticals and served as CFO at Affymax. He began his career at Arthur Andersen, LLP.

Daniel Adelman, M.D., Acting Chief Medical Officer

Dr. Adelman serves as the Acting Chief Medical Officer of Jasper Therapeutics.

Luca Di Noto, Ph. D., Vice President, Technical Operations

Dr. Di Noto joined Jasper Therapeutics in 2020 and has extensive industry experience in process development, process scale-up, technology transfer, cGMP manufacturing, and regulatory submissions for biologic drugs. Previously, he spent five years at Portola Pharmaceuticals as the Head of Drug Substance manufacturing, where he oversaw the Andexxa® program.

Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine

Dr. Pang joined Jasper Therapeutics in 2020 and has led early research and development, including the creation of the company's mRNA stem cell graft platform and played a pivotal role in advancing JSP191 through multiple clinical studies. Prior to Jasper, she was an Instructor in the Division of Blood and Marrow Transplantation at Stanford University and the lead scientist in the preclinical drug development of an anti-CD117 antibody program.

The key risks to Jasper Therapeutics (JSPR) primarily stem from its nature as a clinical-stage biotechnology company focused on the development of novel therapeutic agents.

1. Clinical Trial and Regulatory Approval Risk: As a clinical-stage company, Jasper Therapeutics' success is heavily dependent on the successful outcome of its ongoing and future clinical trials for its lead product candidate, JSP191, and other product candidates. The drug development process is inherently lengthy, costly, and carries a high risk of failure due to unforeseen safety issues, lack of efficacy, or challenges in manufacturing. Even if clinical trials are successful, there is no guarantee that its product candidates will receive the necessary regulatory approvals from agencies like the FDA, which is a complex and often unpredictable process. Failure at any stage of clinical development or inability to obtain regulatory approval would significantly jeopardize the company's future prospects.
2. Reliance on a Single Lead Product Candidate: Jasper Therapeutics' business is highly concentrated around the development of JSP191, described as its "lead product candidate." This heavy reliance means that the company's valuation and future success are predominantly tied to the successful development, approval, and commercialization of JSP191. Any adverse events, delays, or outright failure of JSP191 in clinical trials or regulatory review would have a substantial negative impact on the company, as its pipeline of other engineered hematopoietic stem cell product candidates appears to be in earlier stages of development.
3. Capital and Funding Risk: As a clinical-stage biotechnology company without revenue-generating commercial products, Jasper Therapeutics requires substantial ongoing capital to fund its extensive research and development activities, particularly the costly clinical trials for JSP191 and other candidates. There is a continuous need to raise additional capital, and the company's ability to do so on favorable terms, or at all, is uncertain. A lack of sufficient funding could force the company to delay, scale back, or even abandon its development programs, thereby impacting its ability to bring products to market.

Jasper Therapeutics (NASDAQ: JSPR) operates in several significant addressable markets through its main product candidates, JSP191 (Briquilimab) and its engineered hematopoietic stem cell platform.

JSP191 (Briquilimab)

JSP191, also known as Briquilimab, is being developed for multiple indications, including as a conditioning agent for hematopoietic stem cell transplantation (HSCT) and for chronic conditions such as chronic urticaria and asthma.

• Hematopoietic Stem Cell Transplantation (HSCT): The global hematopoietic stem cell transplantation market was valued at approximately USD 3.25 billion in 2024 and is projected to reach USD 7.89 billion by 2032. Another estimate places the global market at USD 6.7 billion in 2024, growing to USD 10.7 billion by 2030. North America accounts for a substantial portion of this market, holding approximately 38% in 2024. The U.S. hematopoietic stem cell transplantation market alone was estimated at USD 2.58 billion in 2024 and is projected to reach approximately USD 3.87 billion by 2030.
• Chronic Urticaria: The global market size for chronic urticaria was estimated at USD 2.45 billion in 2022 and is expected to grow to USD 7.5 billion by 2029.
• Asthma: The global asthma market size was estimated at USD 18 billion in 2019 and is projected to reach around USD 32.81 billion by 2032.

Engineered Hematopoietic Stem Cells

Jasper Therapeutics is also advancing a preclinical mRNA hematopoietic stem cell grafts platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. This product falls within the broader cell and gene therapy and stem cells markets.

• Global Gene Therapy Market: The global gene therapy market was valued at USD 9.5 billion in 2024, grew to USD 11.4 billion in 2025, and is projected to reach approximately USD 58.87 billion by 2034. North America dominated the gene therapy market with a revenue share of 45% in 2024. The U.S. gene therapy market alone was estimated at USD 6.3 billion in 2025 and is projected to surpass approximately USD 38.4 billion by 2035.
• Global Cell and Gene Therapy (CGT) Market: The global cell and gene therapy sector was valued at USD 18 billion in 2023 and is projected to reach approximately USD 97 billion by 2033.
• Global Stem Cells Market: The global stem cells market size was estimated at USD 15.10 billion in 2024 and is anticipated to reach USD 28.89 billion by 2030. North America accounted for the largest revenue share of 43.89% in the stem cell market in 2024.

For Jasper Therapeutics (JSPR), a clinical-stage biotechnology company, expected drivers of future revenue growth over the next 2-3 years primarily revolve around the advancement of its pipeline and the securing of associated milestone payments or collaborations, rather than direct product sales, as analysts forecast no product revenue in this timeframe. The company's current revenue streams are largely driven by collaboration agreements and government grants, which are tied to research milestones.

The key drivers for potential revenue growth include:

1. Successful Clinical and Regulatory Advancement of Briquilimab in Chronic Urticaria (CSU/CIndU): Briquilimab (formerly JSP191) is Jasper Therapeutics' lead product candidate, with ongoing BEACON and SPOTLIGHT clinical studies for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Positive data readouts, progression to registrational trials, and potential regulatory submissions or designations within the next 2-3 years could trigger significant milestone payments from existing or new collaboration partners. The potential for market approval for chronic urticaria by 2027 could lead to substantial revenue opportunities.

2. Advancement of Briquilimab into Later-Stage Clinical Development for Asthma: Jasper Therapeutics has initiated a new clinical program for briquilimab in asthma. Successful progression through early-stage clinical trials and into later-stage development could attract further partnership interest and associated milestone payments, opening up another potentially large market.

3. Achievement of Clinical Milestones in JSP191's Conditioning Programs for Stem Cell Transplantation: While the company has reprioritized briquilimab for chronic mast cell diseases, JSP191 continues to be developed as a conditioning agent for hematopoietic stem cell transplantation in various indications such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), severe combined immunodeficiency (SCID), Fanconi anemia, and Sickle Cell Disease. Positive clinical data or the initiation of pivotal studies in these areas could lead to additional collaboration revenue through milestone payments.

4. Formation of New or Expanded Strategic Partnerships and Collaboration Agreements: As a clinical-stage biotechnology company, a significant portion of Jasper Therapeutics' reported revenue historically comes from collaboration agreements and government grants. Securing new strategic partnerships or expanding existing collaborations can provide crucial upfront payments, research funding, and development milestone payments, directly contributing to the company's revenue growth within the forecast period.

Share Issuance

• Jasper Therapeutics successfully completed a $30 million underwritten public offering of common stock and warrants in September 2025, extending its cash runway through the first half of 2026.
• In January 2023, the company raised an estimated $101.4 million in net proceeds through a public offering and sales via an at-the-market facility, expected to fund operating and capital expenditures through 2024.
• On September 24, 2021, Jasper Therapeutics consummated a Business Combination, merging with Amplitude Healthcare Acquisition Corporation, resulting in its common stock being listed on Nasdaq under the symbol JSPR.

Inbound Investments

• The company's primary inbound investments within the last three to five years have been through public equity offerings to fund its clinical development programs and general operations.
• Institutional investors held approximately 78% of Jasper Therapeutics' stock as of December 2025, indicating significant external investment in its shares.

Capital Expenditures

• Capital expenditures for the annual period ending December 30, 2024, were -$0.6 million.
• The net proceeds from the September 2025 public offering were allocated for continued advancement of preclinical and clinical development programs, general corporate purposes, including capital expenditures, working capital, and administrative expenses.
• Research and development (R&D) expenses, a significant component of the company's operational spending, were $14.4 million in Q3 2025, $34.6 million in 2022, and $25.4 million in 2021.